ZVRA logo

ZVRA
Zevra Therapeutics Inc

24,160
Mkt Cap
$571.64M
Volume
964,555.00
52W High
$13.16
52W Low
$7.16
PE Ratio
6.47
ZVRA Fundamentals
Price
$9.67
Prev Close
$9.90
Open
$9.83
50D MA
$9.56
Beta
0.81
Avg. Volume
1.49M
EPS (Annual)
$1.35
P/B
3.55
Rev/Employee
$1.75M
$385.27
Loading...
Loading...
News
all
press releases
Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday
Zevra Therapeutics (NASDAQ:ZVRA) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued a buy...
MarketBeat·14d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday...
MarketBeat·19d ago
News Placeholder
Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA
Stratos Wealth Partners LTD. increased its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 78.6% in the 4th quarter, according to its most recent filing with the SEC. The fund...
MarketBeat·23d ago
News Placeholder
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA
JPMorgan Chase & Co. lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 1,458.8% in the third quarter, according to its most recent filing with the SEC. The firm...
MarketBeat·26d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA
Hennion & Walsh Asset Management Inc. acquired a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 139,591 shares of the company's sto...
MarketBeat·27d ago
News Placeholder
John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K
read more...
Benzinga·1mo ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat Ratings...
MarketBeat·1mo ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Up - Still a Buy?
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Up - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research
BTIG Research began coverage on shares of Zevra Therapeutics in a research note on Monday. They issued a "buy" rating and a $23.00 target price on the stock...
MarketBeat·1mo ago
<
1
2
...
>

Latest ZVRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.